Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'

April 10, 2026 1:20 PM

Jefferies analyst Michael Yee reiterated a Buy rating and $12.00 price target on Iovanace Biotherapeutics (NASDAQ: IOVA).The analyst comments "Net-net ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found